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Abstract
Background: In most countries, genetic carrier screening is neither offered, nor embedded in mainstream
healthcare. Technological developments have triggered a two-fold transition in carrier screening: the expansion
from screening one single disorder to many disorders simultaneously, and offering screening universally, regardless
of ancestry. This study aims to identify general and population-specific barriers and needs reflected by stakeholders
regarding the implementation of carrier screening in a changing landscape.
Methods: Seventeen semi-structured interviews were conducted with Dutch key stakeholders working in the
practical and scientific field of carrier screening. The constellation approach was used to categorise barriers and
needs into three levels: culture, structure and practice.
Results: Barriers on a cultural level include: undecidedness about the desirability of carrier screening, and a lack of
priority of screening in mainstream healthcare. On a structural level barriers included: need for organisational structures
in healthcare for embedding carrier screening, need for guidelines, financial structures, practical tools for overcoming
challenges during counselling, and a need for training and education of both professionals and the public. A lack of
demand for screening by the public, and a need for a division of responsibilities were barriers on a practical level.
Conclusion: The absence of a collective sense of urgency for genetic carrier screening, a lack of organisational
structures, and uncertainty or even disagreement about the responsibilities seem to be important barriers in the
implementation of carrier screening. Stakeholders therefore suggest that change agents should be formally
acknowledged to strategically plan broadening of current initiatives and attune different stakeholders.
Keywords: Carrier screening, Expanded universal carrier screening, Implementation, Stakeholders, Interviews, Barriers, Needs
Background
Genetic carrier screening enables couples to find out
whether they are both carriers of the same autosomal
recessive (AR) disorder, and consequently face a 1-in-4
risk of having an affected child in each pregnancy. The
aim of carrier screening is to provide carrier couples with
autonomous reproductive choice [1]. Screening is prefera-
bly done before pregnancy (preconception) as this pro-
vides couples with most reproductive options [2]. These
are, for example, refraining from having children, prenatal
diagnosis, and preimplantation genetic diagnosis.
In many countries, there has been discussion about the
implementation of carrier screening. Currently, screening
practices are mostly aimed at high-risk groups, i.e.
ancestry-based carrier screening. The Ashkenazi Jewish
(AJ) community, for example, has been familiar with carrier
screening since the 1970s, starting with screening for Tay--
Sachs disease [3]. In England, ancestry-based prenatal
haemoglobinopathy (HbP; sickle cell disease, thalassaemia)
carrier screening is conducted in low prevalence areas,
whereas universal screening, regardless of ancestry, is of-
fered in high prevalence areas [4]. In the United States (US)
carrier screening for cystic fibrosis (CF) has been offered
preconceptionally or early in pregnancy for over a decade,
initially ancestry-based, and since 2011 universally [5].
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In most countries, carrier screening has not been imple-
mented on a structural level, and the initiatives that do
exist are mostly local or small niches developed from a re-
search perspective [6–9]. For those niches, research has
been done to identify possible enabling and inhibiting
factors for its implementation and embedding in
mainstream healthcare. Challenges or barriers frequently
mentioned are: a lack of awareness and knowledge among
both the general public and professionals [10–12]; difficul-
ties reaching the target groups, particularly couples
planning a pregnancy [10, 11]; professionals being un-
aware of available guidelines [11, 13]; and a lack of struc-
ture in which to embed genetic carrier screening [10, 11].
Technological developments in genetics such as Next
Generation Sequencing, and cost reductions [14] have trig-
gered a two-fold transition in carrier screening: the expan-
sion of screening from one single disorder to screening for
many disorders simultaneously (‘expanded’), and the transi-
tion of an ancestry-based offer towards an offer of screening
regardless of ancestry or geographical origin (‘universal’)
[15]. Expanded universal carrier screening (EUCS) panels in-
cluding over 100 disorders, are increasingly available from
commercial laboratories in North-America, Australia and
Europe [1, 16], and are increasingly being offered to the
public [14]. A frequently mentioned advantage of EUCS is
that it will reduce stigmatisation and increase equity [1, 17].
However, these advantages may not be as evident as stated.
In 2014 and 2015, we conducted an interview study among
key stakeholders in which they expressed moral concerns re-
garding, for example, the question of whether EUCS will
lead to a lower level of care for high-risk populations, or
reinforce disability-based stigmatisation [15]. This was also
described in a US focus group study by Cho et al. [18].
In the Netherlands, carrier screening is neither routinely
offered, nor embedded in mainstream healthcare [19, 20].
In 2007, the Health Council of the Netherlands recom-
mended studying both an offer of carrier screening for CF
and HbPs in a large pilot, and the structural implementa-
tion of preconception care [21]. However, up till now, these
recommendations have not been followed up, and carrier
screening is only offered as local initiatives. In a Dutch
founder population, screening for four AR disorders is
available [8], a panel for nine disorders for the AJ commu-
nity has been developed in two clinical genetic centres [22],
and a few midwifery practices routinely offer ancestry-
based prenatal HbP carrier screening for women at high
risk [23]. Furthermore, despite the recognised importance
of preconception care in general, this is only offered on a
small scale, and not in a uniform manner [24]. In light of
this context and the technological advances triggering the
current transition in carrier screening, this paper aims to
identify general and population-specific barriers and needs
reflected by Dutch stakeholders regarding the implementa-
tion of (expanded universal) carrier screening.
Methods
A qualitative study design was used and semi-structured
interviews were held with key Dutch stakeholders in the
practical and scientific field of carrier screening between
December 2014 and September 2015. This qualitative
research method was used to capture the range and
diversity of perceived barriers and needs among different
stakeholders. The Medical Ethical Committee of VU
University Medical Center Amsterdam approved the
study protocol.
Theoretical framework
To describe the transition in carrier screening, and to
structure the stakeholders’ views related to carrier screen-
ing, the so-called “constellation perspective” as described
by Van Raak (2010) [25] was used. In this constellation
perspective, there is a continuous interaction between
three main elements of a larger societal system: the cul-
ture, the structure and the practice. Here, culture has been
defined as “the set of shared values, perceptions, and inter-
pretative frames of the involved actors” (e.g. perceptions
regarding carrier screening), structure referred to how
things are physically, financially, and institutionally orga-
nised, and practice involved the actual actions undertaken
by the actors (individuals or groups) within the constella-
tion (e.g. the interaction between patient and professional)
[25]. Culture and structure are both structuring elements,
and are shaped by the common practices of actors. At the
same time, the actors’ actions are also influenced by the
culture and structure of the constellation [25].
In general, the dominant constellation in medicine is
often determined by a group of actors that are familiar
with working according to a certain culture (thinking),
structure (organising), and practice (doing). However, in-
ternal and/or external influences may cause this dominant
constellation to be susceptible for change. These driving
forces of change can originate from dynamics in organisa-
tion, demand, acceptability and/or technology [26]. Espe-
cially recent technical developments on EUCS make the
current situation in carrier testing in healthcare suscep-
tible to moving beyond ancestry-based screening.
Recruitment and participants
A Network of Actors model [11, 26] was used to identify
relevant stakeholder groups: scientists, including laboratory
scientists, developing tests, healthcare professionals offering
tests, citizens that might have a demand for carrier screen-
ing (e.g. patient organisations), and institutions developing
policy and regulations (e.g. policy makers) (Fig. 1). Perspec-
tives of the public are described elsewhere [20].
Stakeholders were non-randomly recruited from all four
groups in the Network of Actors model [11], using role-
based purposeful sampling. Stakeholders were selected
based on their previous experience with carrier screening
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or because others identified them as having an important
viewpoint on this topic. This sampling strategy resulted in
twenty-five stakeholders who were approached for partici-
pation. Stakeholders were informed about the study and
invited to participate via email. Of the people approached,
three refrained as they were no longer involved in the
topic or could not represent the organisation they worked
for, and one interview was cancelled. Four people did not
respond to the initial invitation and reminders. In total,
seventeen interviews were conducted, after which data
saturation was reached, and recruitment and data collec-
tion stopped. Five interviews were performed by two in-
terviewers (EV/SvdH and KH) and the other twelve by a
single interviewer (EV or KH). Interviews were conducted
face-to-face, by telephone or via Skype. Informed consent
was signed by all participants before the start of the inter-
views, and the conversations were audio recorded. Within
two weeks, all interviewees received a summary of the
interview for member checking.
Interview guide
A semi-structured interview guide was developed by
means of the literature, and the constellation perspective
where its three main elements (culture, structure and
practice) served as a basis for the formulation of interview
questions. The guide covered the following topics: stake-
holders’ previous experience with (offering) carrier screen-
ing, opinions on offering carrier screening, both ancestry-
based and EUCS, opinions about (own) responsibility re-
garding the implementation of carrier screening and
collaboration, views on the embedding of carrier screening
in healthcare, and thoughts about commercial offers of
carrier screening (see Additional file 1 for the interview
guide). The results focussing on the moral considerations
and the proposed benefits of EUCS are presented else-
where [15]. During each interview, the questions were
slightly adapted to the stakeholders’ specific knowledge
and role.
Data preparation and analysis
All interviews were typed out verbatim and thematic con-
tent analysis was performed. Coding started with reading
all transcripts in detail, and labelling all recurring topics.
All labels were ranked and clustered into main and
subtopics based on the three main elements, i.e. culture,
structure and practice, of the theoretical framework in
Fig. 1 Interviewees categorised by the four different stakeholder groups in the Network of Actors model (adapted from [26]). 1One stakeholder is
a researcher and a midwife, but is only assigned to the scientists/researchers group
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order to identify important themes. Interviews were coded
by three researchers independently (KH, EV and LH), and
differences in coding were discussed until consensus was
reached. Representative quotes were translated into
English and are presented to illustrate the findings.
Results
The interviews with key stakeholders revealed barriers
and needs regarding the implementation of carrier
screening that were clustered into themes on the three
different levels of the constellation perspective (Table 1).
Culture: changing the way of thinking
The two main themes identified as important for chan-
ging culture regarding genetic carrier screening were de-
sirability and prioritisation.
Desirability
Generally, respondents were positive about offering carrier
screening, but the desirability was also debated and seemed
to depend on two main considerations: the “who” — who
should be offered screening: high-risk groups (ancestry-
based) vs. population-wide — and the “what” — what disor-
ders should be tested for. Carrier screening was considered
more obvious for high-risk groups suffering from specific
disorders, e.g. screening in populations of African ancestry
or in founder populations. Reasons for preferring this were
that these populations are at increased risk of being a car-
rier of several disorders, and that there was a degree of rec-
ognisability of the specific disorders for the high-risk
groups. Disadvantages mentioned were an increasingly
multi-ethnic society, concerns about the registration of eth-
nicity, and the risk of stigmatisation. Some therefore argued
that screening should be offered more universal, as this
would reduce the risk of stigmatisation. They, however, also
indicated that such a population-wide offer would be too
expensive and could lead to ethical dilemmas such as med-
icalisation of pregnancy and eugenics.
“In my opinion, it should not be offered to everyone, as
you will then medicalise the pregnancy”. (#12,
healthcare professional)
Regarding the inclusion of disorders in screening, stake-
holders felt that there was a broad range of criteria that
could be used, e.g. severity, prevalence and lethality of the
disorder, the impact on quality of life, and the burden for
parents. Many stakeholders therefore expressed a need for
setting clear criteria that disorders have to meet in order
to be included in a panel by a multidisciplinary team in-
cluding all key actors (citizens, scientists, health profes-
sionals, and institutions), or by the Dutch Health Council.
Focussing on the implementation of EUCS more specific-
ally, stakeholders indicated that much can be learned from
existing initiatives or niches on carrier screening, both
ancestry-based and EUCS. One of the specific points to
consider was the absence of an active demand by the pub-
lic, apart from specific high-risk groups, for such an offer.
According to the stakeholders, experiences from the
current niches should clarify whether there is an actual
demand for screening and more specifically what kind of
offer (ancestry-based vs. EUCS) is preferred.
Prioritisation
A more generic theme arising from the interviews was the
lack of priority for genetics in general in mainstream
healthcare. Healthcare professionals indicated that offer-
ing carrier screening has no priority in daily practice, as
the emphasis is mainly on curing patients instead of public
health offers to healthy people (prevention). Moreover,
they argued that when attention is paid to preventive as-
pects, professionals especially focus on traditional public
health interventions targeting the well-known risk factors
such as smoking and drinking during pregnancy, instead
of on discussing genetic risks as genetic disorders were
seen as rare.
“You know, we still have to put everything in
perspective. […] And, I think that quitting smoking has
a bigger impact on someone’s health and unborn
children at this moment.”(#13, healthcare professional)
Additionally, stakeholders acknowledged the influence
of the government and its changing policy regarding pub-
lic health offers and preventive measures to healthy
people. One of the stakeholders illustrated this by refer-
ring to the report Preconception care: a good beginning
published by the Health Council of the Netherlands in
2007 [21], stressing the importance of preconception care.
“And at that time, the former minister was willing to
spend an amount of money on that, so that was good.
But the next minister reversed that, so yeah, up till
now no progress has been made.” (#6 healthcare
professional)
In case of structurally implementing carrier screening,
stakeholders argued that a different mind-set towards pre-
paring for a pregnancy, and the possible role of genetics
and carrier screening is needed. Perceptions about how to
achieve this culture shift differed. While some stake-
holders acknowledged a role for patient organisations,
others pointed out that healthcare professionals and pro-
fessional organisations should take the lead. Additionally,
the parallel was drawn with prenatal screening in the
Netherlands, as pregnant women took a role in agenda
setting themselves by asking for prenatal screening tests.
This could also be the case for carrier screening (Table 1).
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Structure: changing the way of organising
Regarding structure, five themes emerged from the inter-
views: infrastructure; guidelines; financial structures; chal-
lenges during counselling; and training and education.
Infrastructure
Stakeholders perceived the lack of infrastructure in (pri-
mary) healthcare as an important barrier for implement-
ing carrier screening, and discussed whether screening
should be offered as a single screening programme or em-
bedded in preconception care. According to respondents,
when considering the structural implementation of pre-
conception carrier screening, a well-organised infrastruc-
ture for preconception care in general, and guidelines are
needed. Though preconception care was seen as a possi-
bility, many stakeholders also raised concerns, e.g. the lack
of knowledge among health professionals and the target
population, and the lack of funding. Stakeholders further-
more argued that carrier screening should not necessarily
be offered by one profession only. A proposed alternative
was a structure where genetic carrier screening is offered
by multiple providers: general practitioners, midwives,
youth healthcare physicians, gynaecologists, clinical genet-
icists, and genetic counsellors. Though other providers
were mentioned as well, most stakeholders agreed that
screening should be offered by a medically trained profes-
sional to assure sufficient counselling. In light of the dif-
ferent potential providers, stakeholders also suggested
different moments in time for offering carrier screening.
Although offering screening preconceptionally was pre-
ferred, they also indicated that screening could be offered
prenatally, for example embedded in existing routinely
performed blood tests during pregnancy or between preg-
nancies (interconception care).
When discussing the desirability of a commercial offer,
some stakeholders perceived the developments in commerce
as inevitable, but many also expressed concerns, for example:
doubts about the quality of the test, increasing inequality due
to high costs, and creating a false sense of security.
“I don’t know how reliable these companies are. When
conducting a test outside university hospitals, who are
the experts looking at the mutations then? Or is it just
a fancy programme? It can all be automated. I think
that’s a creepy development.” (#7, scientist/researcher)
Guidelines
Stakeholders also expressed concerns regarding a lack of
guidelines, complicating the offer of carrier screening or
even informing people about it. Most respondents did
acknowledge that some information was available, but it
was often not in the right place, making it difficult to find
or use. Stakeholders therefore outlined the need for
adequate and accessible guidelines concerning indications
for screening and issues that need to be addressed during
pre- and post-test counselling. The development and ad-
justment of guidelines, however, was considered to be
complex. Obstacles mentioned by stakeholders were the
lack of financial resources, lack of time, and the many par-
ties involved in designing guidelines.
Financial structures
Much uncertainty about the exact costs of carrier screen-
ing was expressed by the stakeholders, and in cases where
the prices were known, they were perceived as high and
unacceptable.
“One of the arguments is that it is unethical, because
the costs of those tests, you know, that is questionable,
and a CF test is of course very expensive. Look, HbP
that’s a tenner, but a CF test is quite pricey.” (# 2,
scientist/researcher)
This discussion seemed to be especially crucial when
considering the implementation of EUCS. Despite the
expectation that costs of carrier screening will decrease
due to current technological developments, costs of test-
ing and counselling remain substantial. Stakeholders ar-
gued that given the autonomy of possible users,
attention should be paid to ensure equity of access. Ac-
cording to them, excessively high costs of screening
might exclude people with a lower socio-economic sta-
tus who might, for example, be more prone to HbPs in
the Netherlands and would benefit most from screening.
The autonomy principle is then violated. However, one
respondent argued that it would be good to have people
pay a small amount for screening as she thought that
people would then make a more considered decision.
Furthermore, it was mentioned that when discussing the
embedding of carrier screening within preconception
care, uncertainty about the reimbursement of such a
consultation should be clarified first.
Challenges during counselling
Stakeholders expressed two challenges encountered dur-
ing counselling for carrier screening. They acknowledged
that people should receive sufficient information in
order to make an informed decision about having
screening or not. However, the complexity of the subject
makes it difficult for healthcare professionals to provide
this information. As counselling for ancestry-based
screening for one or several disorders was already per-
ceived as something complicated, stakeholders expected
even more difficulties when offering EUCS.
“You will have to explain the disorders properly. You
have to explain life expectancy, and what it means to
live with such a disorder. You will certainly be asked:
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can you cure this? You have to explain that very well.
Is it treatable when we detect it in an early stage, can
we cure it? […] And when it is a broad range of
disorders, well you can imagine that it is too much
information.” (#15, healthcare professional)
Another stakeholder drew the parallel with the expansion
of neonatal screening, from one to seventeen disorders over
the years in the Netherlands, and argued that information
could be provided in a layered fashion. Healthcare profes-
sionals can provide general information during counselling
and refer to information leaflets or the internet for detailed
information. Information can also be provided by ambassa-
dors from their home country in their mother tongue. Fur-
thermore, stakeholders argued that counselling for carrier
screening requires a paradigm shift from directive advices
to non-directive counselling. In order to tackle this, they
expressed a need for practical tools (e.g. practice instruc-
tions – schematic overview of points to be discussed) that
deal with the actual knowledge, and how to interpret lab re-
sults, but also include specific examples of how to counsel
in a non-directive way.
Training and education
Stakeholders believed that sufficient knowledge about
genetics and carrier screening is essential but also indi-
cated that this important aspect is often lacking. Profes-
sionals are, however, not the only ones struggling with a
lack of awareness and knowledge. Stakeholders indicated
that the general public’s knowledge is also insufficient:
“A bottleneck is, for example, the fact that men think
they could never be a carrier when a baby is
diagnosed with sickle cell disease because a baby has
spent nine months in the mother’s womb, so it is
always transferred by the mother”. (#3, healthcare
professional)
According to the stakeholders, the establishment of edu-
cational structures for both professionals and citizens are
key in the implementation of carrier screening. They felt
that more attention should be paid to genetics education in
general, and carrier screening more specifically, by assign-
ing a central role to this topic in the curricula of medicine
students, and in postgraduate education for health profes-
sionals. Regarding informing the public, stakeholders ar-
gued that information can be provided by means of a
media campaign or incorporating information in secondary
education. As information should be accessible for every-
one, illiteracy should also be taken into account.
Practice: changing the way of doing
Two main practice-related themes emerged from the in-
terviews as being of importance in the implementation
of genetic carrier screening: demand for carrier screen-
ing and responsibility.
Demand for carrier screening
Stakeholders pointed out that the public can also influ-
ence implementation. When carrier screening is actually
frequently requested in daily practice, healthcare profes-
sionals are most likely to be more willing to offer it.
However, stakeholders argued that when it comes to
preconception carrier screening, talking about a preg-
nancy wish might be perceived as taboo, and actively
requesting and discussing information with healthcare
professionals before conceiving is not yet self-evident.
“It has also to do with the fact that it’s not self-evident
that people will actively look for information them-
selves before starting a family.” (#4, representative of a
patient organisation)”
At the same time, stakeholders questioned whether indi-
viduals actually do something with the information about
being a carrier; what are the consequences of knowing?
Multiple stakeholders felt this should be studied further.
Responsibility
Responsibility was considered important and expressed as
a clear need when discussing the implementation of car-
rier screening. However, according to stakeholders this is
lacking at the moment. They argued that the government
delegates the responsibility for the implementation of car-
rier screening to the healthcare professionals, whereas
professionals generally expect the government to step in
and take the responsibility to organise the debate about
screening and to develop policy. However, an important
nuance raised by one of the stakeholders is that placing
the responsibility of execution with the government may
also be misinterpreted. The neonatal screening and the
vaccination programme were used as an illustration as al-
though participation in these programmes is voluntary, a
high uptake is pursued. Since a high uptake is not the pri-
mary aim when offering carrier screening, and mixed mes-
sages are to be avoided, stakeholders thought that the
responsibility could also be assigned to an independent
non-commercial organisation instead of the government.
Discussion
This study identified different barriers and needs regard-
ing the implementation of genetic carrier screening in a
changing landscape by interviewing key stakeholders.
They argued that, apart from requests in specific high-
risk populations, there is still no actual demand for
ancestry-based nor expanded universal carrier screening
(EUCS) from the general population in daily practice,
and a lack of priority for genetics and public health
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offers to healthy people planning to have children in
mainstream healthcare. If an offer of genetic carrier
screening were found to be desirable, stakeholders
expressed a need for structural changes: a need for an
infrastructure in healthcare for implementing carrier
screening, a need for guidelines, financial and educa-
tional structures, and practical tools for counselling.
Moreover, they felt a strong need for a clear division of
responsibilities.
Since the current screening offers of EUCS are mainly
technology-driven, it is important to attune to the actual
demand [20]. After all, in the absence of demand, should
we then continue offering? On the other hand, an offer
can possibly generate demand as many people are not fa-
miliar with carrier screening yet, and can thus initiate an
innovation curve. Previously, we have shown that the de-
mand for screening may be influenced by awareness of
and familiarity with genetic diseases and carrier screening
[20]. While it has been acknowledged that in specific
high-risk groups there is an actual demand for ancestry-
based carrier screening [3, 7, 8], this is not yet evident for
EUCS. However, a public health initiative for a
population-wide screening offer is often not a reaction to
individual requests, but a response to a significant public
health problem, based on the need of (groups of) parents
or physicians of children with a severe genetic disorder. A
classic example is new-born screening for PKU, the first
population screening program for a rare disease in many
countries. Especially this aspect might explain why stake-
holders stress the importance of an offer of carrier screen-
ing despite the limited individual demand.
Most stakeholders found an offer of ancestry-based
carrier screening to be desirable, as was also described
in the literature [27–29]. The desirability and acceptance
of EUCS were, however, less obvious. Stakeholders
expressed both practical and moral dilemmas [15], as
was also shown by others [30, 31]. One dilemma con-
cerned determining which disorders and how many
should be included in a screening panel, and stake-
holders acknowledged the importance of clear inclusion
criteria set by a multidisciplinary team. Based on health-
care professionals’ opinions Lazarin et al. proposed a
classification of disease severity for the inclusion in
EUCS [32]. Stakeholders in our study furthermore feared
that EUCS might lead to the medicalisation of pregnancy
and to eugenics. These particular dilemmas were also
mentioned in a Swedish interview study among health
professionals [33]. We, and others, have also described
that rather than increasing equity of access, EUCS might
hinder this when specific mutations for high-risk groups
were not included in the screening panels [15, 18].
Stakeholders also stressed that within healthcare, the
priority (i.e. allocating time and money) is given to curing
patients instead of to public health offers to healthy people
(prevention). In the Swedish interview study, stakeholders
expressed concerns about the costs of expanded carrier
screening and the effects of its implementation on the
budgeting of other healthcare areas. They indicated that
money could better be spent on more vital diseases such
as cancer [33]. In the case of insufficient resources, it is
necessary to determine which tests are most important to
provide, bearing in mind that allocating healthcare re-
sources fairly requires the use of ethically reflected criteria
[34]. Claims based on health and intervention need, e.g.
the a priori probability of having a disease, appear to serve
as the strongest normative basis [34]. Accordingly,
ancestry-based carrier screening may be considered to
have a higher need than EUCS, but the reverse can be ar-
gued as well: a service offering a carrier test for 100+ dis-
eases has a higher chance of recognising carrier status of
any disease than a service just testing for one disease, thus
potentially generating more value.
Regarding the need for the development of organisa-
tional structures and ancillary matters such as guidelines,
stakeholders did mention the potential of preconception
care, but also the practical challenges involved. Other
studies also report the many barriers that implementation
encounters, for example, time constraints faced by health-
care professionals, few women attending preconception
care consultations, and costs [24, 35, 36]. In the absence
of a solid structure, it was suggested that screening could
be offered at different moments in time by several pro-
viders. One of the options mentioned was interconception
care, i.e. care provided between pregnancies, and that a
specific role could be assigned to youth healthcare physi-
cians providing preventive child healthcare. The potential
of interconception care to new mothers is increasingly be-
ing discussed in the literature, and it is stated that its
unique position to reach women and its expertise in pre-
ventive healthcare are facilitating factors [37, 38]. How-
ever, a disadvantage could be that in some cases, parents
have already been confronted with the birth of an affected
child without being aware of their increased risk. Another
option might be a commercial structure. Though some re-
spondents expected this to be an inevitable development,
many expressed concerns: a lack of pre- and post-test
counselling, and doubts about the quality of the test.
These concerns have also been reported elsewhere [1, 16,
33], and already in 2010 policy on advertising and the
provision of predictive genetic tests by so-called direct-to-
consumer companies has been developed [39]. Without a
clear structure within healthcare, commercial companies
could potentially play a role in offering carrier screening,
but the policy recommendations also apply [1, 39]. Thus
proper monitoring and evaluation is needed here too.
However, specific attention should be paid to the possibil-
ity of contributing to socio-economic inequalities by offer-
ing screening commercially [40].
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In discussing who should take the responsibility or initia-
tive for implementing genetic carrier screening or even de-
veloping organisational structures for preconception care
in general, stakeholders continuously refer to each other.
Given the Dutch legislation [41], this is not surprising since
both parties (i.e. healthcare providers and public health au-
thorities) find support for their viewpoints. Prevention is in
many respects legally a responsibility of municipalities, but
the maintenance and improvement of a support structure
are national responsibilities. The Dutch policy on prenatal
screening could serve as an example here, as indeed sup-
port structures to guarantee quality are a national responsi-
bility [42]. To move forward, it is crucial to effectuate a
new division of responsibilities. This can, for example, be
achieved by having governments adopt an active role in
discussing the responsible introduction of expanded car-
rier screening, as was suggested in recommendations by
the European Society of Human Genetics [1], and in an
Australian review on current CF carrier screening prac-
tices and the progress towards establishing a universal
programme [43]. Another possibility might be acknow-
ledging key actors (also referred to as “change agents”
[26]) who are able to attune different stakeholders, and
strategically plan the implementation of carrier screening.
The barriers and needs expressed by stakeholders continu-
ously interact. A so-called collective sense of urgency among
all key stakeholders is crucial for implementation in general,
but also for genetics in particular [26]: an offer of carrier
screening should be considered desirable and there should be
an actual demand. When the interviews were conducted, this
collective sense of urgency was far from evident, especially
regarding EUCS. In the absence of an adequate structure and
uncertainties about responsibilities, since 2016, Dutch clinical
genetic centres of two university hospitals have taken the re-
sponsibility, and initiated the development of two new initia-
tives of offering EUCS. One comprises an offer via general
practitioners within a research setting [44], and the other in-
volves offering EUCS, non-reimbursed, via the clinical genet-
ics department of a university hospital in Amsterdam [45].
Evaluation of uptake and outcomes of these initiatives will
give insight in whether there is a demand for such an offer.
Furthermore, arguments for testing and experiences with
EUCS could be studied further.
Strengths and limitations
By using a qualitative design, a broad range of barriers
and needs regarding the implementation of carrier screen-
ing in a changing landscape was revealed that would have
been difficult to recognise in a quantitative study. The use
of theoretical frameworks furthermore helped identifying
involved actors, and guiding and structuring the interpret-
ation of the findings. In order to recruit the stakeholders,
a role-based purposeful sampling strategy was used. Stake-
holder were selected based on their previous experiences
with carrier screening to enhance a lively, in-depth discus-
sion about the topic. However, this method also entails
disadvantages, such as, selection bias or an incomplete
sample. To reduce the risk of bias, member checking, and
researcher triangulation were used [46]. Despite the use of
a model for identifying stakeholders, some perspectives
are lacking in this study as for example gynaecologists did
not respond to our invitation, as well as some professional
organisations. Further, the perspective of the public itself
or the citizens was not included, but has been described
elsewhere [20]. Issues that were absent in our results but
that were raised elsewhere, must be included in future
quantitative studies, including specific barriers and needs.
Lastly, as this study has been conducted in a very specific
healthcare context, i.e. in the absence of a routine offer of
carrier screening in mainstream healthcare, results cannot
be directly translated to other countries.
Conclusions
The absence of a collective sense of urgency for carrier
screening, a lack of organisational structures, and uncer-
tainty or even disagreement concerning the division of re-
sponsibilities for implementing and offering screening seem
to be significant barriers to the implementation of genetic
carrier screening. Stakeholders therefore suggest that
change agents should be formally acknowledged to stra-
tegically plan broadening of current initiatives and attune
different stakeholders. By using a theoretical framework for
the identification and clustering of stakeholder perspectives
regarding the implementation of carrier screening, this
study provides a clear overview of relevant and urgent
barriers and needs on different levels (culture, structure,
and practice). These findings allow involved stakeholders to
adequately address most important issues when imple-
menting carrier screening in a changing landscape.
Additional file
Additional file 1: Title of data: Semi-structured interview guide.
This additional file includes the complete interview guide containing:
an introduction to the interview study, the interview questions, and the
closure of the interview. (DOCX 22 kb)
Abbreviations
AJ: Ashkenazi Jewish; AR: Autosomal recessive; CF: Cystic fibrosis;
EUCS: Expanded universal carrier screening; HbP: Haemoglobinopathy;
PKU: Phenylketonuria; US: United States
Acknowledgements
The authors wish to thank all stakeholders who participated in the interviews
and Sanne van der Hout (SvdH) for helping with the interviews.
Funding
The study was funded by the Netherlands Organization for Health Research
and Development (ZonMw grant no.: 209040001) as part of the Regional
Perinatal Network Northwest Netherlands.
Holtkamp et al. BMC Health Services Research  (2017) 17:146 Page 10 of 12
Availability of data and materials
The data that support the findings of this study are available on request from
the corresponding author. The data are not publicly available as they contain
information that could compromise research participant privacy/consent.
Authors’ contributions
The individual contribution of the authors are as follows: KCAH, PL, LH and
MCC contributed to the study conception and design. KCAH and EMV
contributed to the data collection. KCAH, EMV, TR and LH, contributed to the
analysis and interpretation of the data. KCAH, TR, PL, LH, and MCC have been
involved in drafting, and critically revising the manuscript. All authors read
and approved the final manuscript.
Competing interests
All authors are affiliated to a hospital that offers carrier screening in a
non-commercial setting.
Consent for publication
All interviewees agreed to the processing and publication (anonymously) of
the data by signing the informed consent form.
Ethics approval and consent to participate
The Medical Ethical Committee of VU University Medical Center Amsterdam
approved the study protocol. All interviewees signed an informed consent
form prior to the interview.
Author details
1Department of Clinical Genetics, Section of Community Genetics,
Amsterdam Public Health Research Institute, VU University Medical Center,
PO Box 7057 (BS7 A-509), 1007 MB Amsterdam, The Netherlands.
2Department of Clinical Genetics, Academic Medical Center, Amsterdam, The
Netherlands.
Received: 11 November 2016 Accepted: 9 February 2017
References
1. Henneman L, Borry P, Chokoshvili D, Cornel MC, van El CG, Forzano F, et al.
Responsible implementation of expanded carrier screening. Eur J Hum
Genet. 2016;24:e1–e12.
2. de Wert G, Dondorp WJ, Knoppers BM. Preconception care and genetic risk:
ethical issues. J Community Genet. 2012;3:221–8.
3. Kaback MM. Screening and prevention in Tay-sachs disease: origins, update,
and impact. Adv Genet. 2001;44:253–65.
4. NHS. Sickle cell and thalassaemia, handbook for laboratories. 3rd ed. 2012.
5. American College of Obstetricians and Gynecologists. Committee opinion
no. 486. Update on carrier screening for cystic fibrosis. Obstet Gynecol.
2011;117:1028–31.
6. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for beta-
thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18:
1077–83.
7. Zlotogora J, Carmi R, Lev B, Shalev SA. A targeted population carrier
screening program for severe and frequent genetic diseases in Israel. Eur J
Hum Genet. 2008;17:591–7.
8. Mathijssen IB, Henneman L, van Eeten-Nijman JM, Lakeman P, Ottenheim CP,
Redeker EJ, et al. Targeted carrier screening for four recessive disorders: high
detection rate within a founder population. Eur J Med Genet. 2015;58:123–8.
9. Martyn M, Anderson V, Archibald A, Carter R, Cohen J, Delatycki M, et al.
Offering fragile X syndrome carrier screening: a prospective mixed-methods
observational study comparing carrier screening of pregnant and non-
pregnant women in the general population. BMJ Open. 2013;3:e003660.
10. Poppelaars FA, van der Wal G, Braspenning JC, Cornel MC, Henneman L,
Langendam MW, et al. Possibilities and barriers in the implementation of a
preconceptional screening programme for cystic fibrosis carriers: a focus
group study. Public Health. 2003;117:396–403.
11. Achterbergh R, Lakeman P, Stemerding D, Moors EH, Cornel MC.
Implementation of preconceptional carrier screening for cystic fibrosis and
haemoglobinopathies: a sociotechnical analysis. Health Policy. 2007;83:277–86.
12. McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M. “It is not in my
world”: an exploration of attitudes and influences associated with cystic
fibrosis carrier screening. Eur J Hum Genet. 2008;16:435–44.
13. Darcy D, Tian L, Taylor J, Schrijver I. Cystic fibrosis carrier screening in obstetric
clinical practice: knowledge, practices, and barriers, a decade after publication
of screening guidelines. Genet Test Mol Biomarkers. 2011;15:517–23.
14. Benn P, Chapman AR, Erickson K, DeFrancesco MS, Wilkins-Haug L, Egan
JFX, et al. Obstetricians and gynecologists’ practice and opinions of
expanded carrier testing and noninvasive prenatal testing. Prenat Diagn.
2014;34:145–52.
15. van der Hout S, Holtkamp KC, Henneman L, de Wert G, Dondorp WJ.
Advantages of expanded universal carrier screening: what is at stake. Eur J
Hum Genet. 2017;25:17–21.
16. Borry P, Henneman L, Lakeman P, ten Kate LP, Cornel MC, Howard HC.
Preconceptional genetic carrier testing and the commercial offer directly-to-
consumers. Hum Reprod. 2011;26:972–7.
17. Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC, et al.
Expanded carrier screening in reproductive medicine-points to consider: a
joint statement of the american college of medical genetics and genomics,
american college of obstetricians and gynecologists, national society of
genetic counselors, perinatal quality foundation, and society for maternal-
fetal medicine. Obstet Gynecol. 2015;125:653–62.
18. Cho D, McGowan ML, Metcalfe J, Sharp RR. Expanded carrier screening in
reproductive healthcare: perspectives from genetics professionals. Hum
Reprod. 2013;28:1725–30.
19. Cornel MC, Lakeman P, Dondorp W. Stel preconceptionele
dragerschapscreening niet uit [Preconceptional carrier screening should not
be delayed]. Ned Tijdschr Geneeskd. 2011;155:A3205.
20. Holtkamp KC, Mathijssen IB, Lakeman P, van Maarle MC, Dondorp WJ,
Henneman L, et al. Factors for successful implementation of population-
based expanded carrier screening: learning from existing initiatives. Eur J
Public Health. 2016;DOI: 10.1093/eurpub/ckw110.
21. Gezondheidsraad [Health Council of the Netherlands]. Preconceptiezorg:
voor een goed begin [Preconception Care: a good beginning]. 2007.
22. Holtkamp KC, van Maarle MC, Schouten MJE, Dondorp WJ, Lakeman P,
Henneman L. Do people from the Jewish community prefer ancestry-
based or pan-ethnic expanded carrier screening. Eur J Hum Genet.
2016;24:171–7.
23. Giordano CP, Harteveld LC, Bakker E. Genetic epidemiology and preventive
healthcare in multiethnic societies: the hemoglobinopathies. Int J Environ
Res Public Health. 2014;11:6136–46.
24. Temel S, van Voorst SF, de Jong-Potjer LC, Waelput AJM, Cornel MC, de
Weerd SR, et al. The Dutch national summit on preconception care: a
summary of definitions, evidence and recommendations. J Community
Genet. 2015;6:107–15.
25. van Raak R. The transition (management) perspective on long-term change
in healthcare. In: Broerse JE, Bunders JG, editors. Transitions in health
systems: dealing with persistent problems. Amsterdam: VU University Press;
2010. p. 49–86.
26. Rigter T, Henneman L, Broerse J, Shepherd M, Blanco I, Kristoffersson U, et
al. Developing a framework for implementation of genetic services: learning
from examples of testing for monogenic forms of common diseases. J
Community Genet. 2014;5:337–47.
27. Henneman L, Bramsen I, van der Ploeg HM, Ader HJ, van der Horst HE, Gille JJ,
et al. Participation in preconceptional carrier couple screening: characteristics,
attitudes, and knowledge of both partners. J Med Genet. 2001;38:695–703.
28. Janssens S, De Paepe A, Borry P. Attitudes of health care professionals
toward carrier screening for cystic fibrosis. A review of the literature. J
Community Genet. 2014;5:13–29.
29. Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, ten Kate LP.
Preconceptional ancestry-based carrier couple screening for cystic fibrosis
and haemoglobinopathies: what determines the intention to participate or
not and actual participation? Eur J Hum Genet. 2009;17:999–1009.
30. Kihlbom U. Ethical issues in preconception genetic carrier screening. Ups J
Med Sci. 2016;121:295–98.
31. Janssens S, Chokoshvili D, Vears D, De Paepe A, Borry P. Attitudes of
european geneticists regarding expanded carrier screening. J Obstet
Gynecol Neonatal Nurs. 2017;46:63–71.
32. Lazarin GA, Hawthorne F, Collins NS, Platt EA, Evans EA, Haque IS.
Systematic classification of disease severity for evaluation of expanded
carrier screening panels. PLoS One. 2014;9:e114391.
33. Matar A, Kihlbom U, Höglund AT. Swedish healthcare providers’ perceptions
of preconception expanded carrier screening (ECS) - a qualitative study. J
Community Genet. 2016;7:203–14.
Holtkamp et al. BMC Health Services Research  (2017) 17:146 Page 11 of 12
34. Rogowski WH, Grosse SD, Schmidtke J, Marckmann G. Criteria for fairly
allocating scarce health-care resources to genetic tests: which matter most?
Eur J Hum Genet. 2014;22:25–31.
35. M’hamdi HI, van Voorst SF, Pinxten W, Hilhorst MT, Steegers EAP. Barriers in
the Uptake and Delivery of Preconception Care: Exploring the Views of Care
Providers. Matern Child Health J. 2017;21:21–28.
36. Mazza D, Chapman A, Michie S. Barriers to the implementation of
preconception care guidelines as perceived by general practitioners: a
qualitative study. BMC Health Serv Res. 2013;13:36.
37. Sijpkens MK, Steegers EAP, Rosman AN. Facilitators and Barriers for Successful
Implementation of Interconception Care in Preventive Child Health Care
Services in the Netherlands. Matern Child Health J. 2016;20(suppl 1):117–24.
38. Rosener SE, Barr WB, Frayne DJ, Barash JH, Gross ME, Bennett IM.
Interconception care for mothers during well-child visits with family
physicians: an IMPLICIT network study. Ann Fam Med. 2016;14:350–5.
39. European Society of Human Genetics. Statement of the ESHG on direct-to-
consumer genetic testing for health-related purposes. Eur J Hum Genet.
2010;18:1271–73.
40. Williams-Jones B. Where there’s a web, there’s a way: commercial genetic
testing and the internet. Public Health Genomics. 2003;6:46–57.
41. Wet publieke gezondheid [Public Health Act]. 2016. http://wetten.overheid.
nl/BWBR0024705/2016-08-01. Accessed 12 Aug 2016
42. van El CG, Pieters T, Cornel M. Genetic screening and democracy: lessons
from debating genetic screening criteria in the Netherlands. J Community
Genet. 2012;3:79–89.
43. Massie J, Ioannou L, Delatycki M. Prenatal and preconception population
carrier screening for cystic fibrosis in Australia: Where are we up to? Aust N
Z J Obstet Gynaecol. 2014;54:503–9.
44. Plantinga M, Birnie E, Abbott KM, Sinke RJ, Lucassen AM, Schuurmans J, et
al. Population-based preconception carrier screening: how potential users
from the general population view a test for 50 serious diseases. Eur J Hum
Genet. 2016;24:1417–23.
45. Academisch Medisch Centrum. Dragerschaptesten [Carrier tests]. 2016.
https://www.dragerschapstest.nl/. Accessed 22 Aug 2016
46. Mays N, Pope C. Assessing quality in qualitative research. BMJ. 2000;320:50–2.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Holtkamp et al. BMC Health Services Research  (2017) 17:146 Page 12 of 12
